Approved Study Database
| Ref. No. | Scientific Title | Principal investigator |
|---|---|---|
| 2020.470 | A retrospective analysis of Helicobacter pylori eradication rate by Clarithromycin based therapy in Hong Kong |
Dr. WONG Ka Hei 黃嘉曦 |
| 2016.040 | A retrospective analysis of a pilot program “Yan Oi Tong - CUHK Traditional Chinese Medicine Music Therapy Pilot Programme” |
Prof. LAU Alexander Yuk Lun 劉玉麟 |
| 2017.055 | A retrospective analysis - would Baylor Bleeding Score be able to identify the patients who are at high risk of rebleeding? | Prof. SUNG Joseph Jao Yiu |
| 2023.682 | A Retrospective & Prospective, Non-Randomized, Clinical Registry of The AngioliteTM Durable Fluoroacrylate Polymer-based Sirolimus-Eluting Stent in The Treatment of Patients with Left Main Coronary Artery Lesions: A Retrospective & Prospective Observational Study. |
Prof. Tan Guangming 譚廣明 |
| 2008.310 | A Retropsective Study to Investigate the Prognostic Significance of p63 EGFR and HER2 Expression in Patients with Head and Neck Squamous Cell Carcinoma | TSE Gary |
| 2009.153 | A Retropsective Study to Compare the Percentage of Ambulance Arrival Case and Non-Ambulance Case Who is Categorized as Urgent (Cat III or above) in Triage | Yuen Chi Wai |
| 2012.432 | A Retropsective Review on the Appropriateness of Acid Suppression Therapy for Stress Ulcer Prophylaxis after Intensive Care Unit Stay | Miss Yeung Shing Yin |
| 2007.489 | A Restrospective Study in Exploring the Effectiveness of ED Nurse-Initiated Asthma Protocol: Optimizing the Clinical Outcomes of Adult Asthma Patients | Dr. WONG Wai Lin Marian |
| 2024.714 | A repeated-measures study on assessing mental health impacts of hot weather among outreach healthcare providers in Hong Kong | Prof. TSE Lap Ah |
| 2024.004 | A repeated-measures study on assessing mental health impacts of hot weather among outreach community nurses in Hong Kong |
Prof. TSE Lap Ah Lap Ah Tse |
| 2006.444 | A Registry to Study the Switch from Existing Insulin Treatment to Another Insulin Treatment in Inadequately Controlled Type 1 & 2 Diabetes Patients | KO Tin Choi Gary |
| 2018.301 | A Registry Study to Assess Patient Reported Outcomes (PRO’s) in Patients with Liver Diseases (CLD-PRO Global Registry Study) |
Prof. WONG Vincent Wai Sun 黃煒燊 |
| 2006.051 | A Registry for Comparing Catheter-Related Infection Rates among Various Shunt Systems in the Treatment of Hydrocephalus | WONG KC George |
| 2023.295 | A Real-life study of Anti-CGRP medication in Asian Patients with migraine (REAP) | Dr. IP Bonaventure Yiu Ming |
| 2018.379 | A real world study evaluating the safety and efficacy of Prolieve in treating men with symptomatic benign prostatic hyperplasia |
Prof. TEOH Jeremy Yuen Chun 張源津 |
| 2018.517 | A rare presentation of intraneural ganglion of the ulnar nerve in the cubital tunnel - A case report |
Dr. MAK Michael Chu Kay 麥柱基 |
| 2004.403 | A Randomized, Three Arm Multinational Phase III Study to Investigate Bevacizumab (q3w or q2w) in Combination with Either Intermittent Capecitabine Plus Oxaliplatin (XELOX) (q3w) or Fluorouracil/Leucovorin With Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 Regimen Alone as Adjuvant Chemotherapy in Colon Carcinoma | Prof. Chan TC Anthony |
| 2002.233 | A Randomized, Third-Party-Blind, Multicentre Study to Assess the Efficacy, Safety, and Cost-effectiveness of Intravenous Sulbactam/Ampicllin Compared with cefuroxime Plus Metronidazole Combination for the Prophylaxis of Infection in Subjects (Including Those with Colorectal Cancer) Following Colorectal Surgery (Ref No cre-2002.233-t)(Revised : cre-2002.033-t) | Prof. Leung Ka Lau |
| 2017.270 | A RANDOMIZED, SPONSOR-OPEN, PLACEBO-CONTROLLED STUDY TO EVALUATE SAFETY, TOLERABILITY AND PHARMACOKINETICS AND PHARMACODYNAMICS OF SUBCUTANEOUS ADMINISTRATION OF RO7062931 WITH SINGLE ASCENDING DOSES IN HEALTHY VOLUNTEERS AND MULTIPLE DOSES AND MODIFIED REGIMENS IN VIROLOGICALLY SUPPRESSED PATIENTS WITH CHRONIC HEPATITIS B VIRUS INFECTION |
Prof. CHAN Henry Lik Yuen 陳力元 |
| 2017.271 | A RANDOMIZED, SPONSOR-OPEN, INVESTIGATOR–BLIND, SUBJECT-BLIND, PLACEBO-CONTROLLED, SINGLE ASCENDING DOSE, TO INVESTIGATE THE SAFETY, TOLERABILITY AND PHARMACOKINETICS OF RO7062931 FOLLOWING SUBCUTANEOUSLY ADMINISTRATION IN HEALTHY CHINESE VOLUNTEERS |
Dr. LUK Andrea On Yan 陸安欣 |
| 2017.451 | A RANDOMIZED, SPONSOR-OPEN, INVESTIGATOR-BLINDED, SUBJECT-BLINDED, PLACEBO-CONTROLLED, SINGLE AND MULTIPLE ASCENDING DOSE STUDY TO EVALUATE THE SAFETY, TOLERABILITY, PHARMACOKINETICS AND PHARMACODYNAMICS OF RO7020531 AND METABOLITES FOLLOWING ORAL ADMINISTRATION TO CHINESE HEALTHY VOLUNTEERS |
Dr. LUK Andrea On Yan 陸安欣 |
| 2005.368 | A Randomized, Single-Dose, Open-Label, Two-Way Crossover Study to Investigate the Pharmacokinetics of HPD-333-A Transdermal System in Healthy Subjects | Prof. Brian Tomlinson |
| 2005.379 | A Randomized, Single-Dose, Cross-Over, Bioavailability Study to Evaluate Propranolol HCI (DDC100105) Sublingual Tablet As Compared With Propranolol HCL (Inderal_) Immediate Release Oral Tablet in Healthy Volunteers | Prof. Chow SS Moses |
| 2013.081 | A Randomized, Single-blinded, Controlled Trial to Investigate the Efficacy of Low-Magnitude High-Frequency Vibration Treatment on Early Stage Osteoarthritic Knee (VTOAK) | Professor Leung Kwok Sui |
| 2006.117 | A Randomized, Single-blind, Parallel Group Pilot Study on the Use of NARL-Sonic Treatment to Induce Fat Mobilization and Visceral Fat Reduction | CHOW CC Francis |
| 2014.578 | A randomized, single-blind, controlled trial of electro-acupuncture for the treatment of symptomatic gallstone diseases | Dr. WONG Wendy |
| 2016.656 | A randomized, single blinded clinical trial on Stem cell therapy in osteochondral lesion associated with different hand and wrist pathology |
Dr. TSE Wing Lim 謝永廉 |
| 2011.568 | A Randomized, Placebo-controlled, Double-blind, Multicenter Phase II Trial of Intravenous GC33 at 1600 mg Q2W in Previously Treated Patients with Unresectable Advanced or Metastatic Hepatocellular Carcinoma (HCC) | Dr Stephen Chan |
| 2009.565 | A randomized, placebo-controlled, double-blind trial of Phyllanthus urinaria (Hepaguard_) in adults with nonalcoholic steatohepatitis | Dr. Wong Wai Sun |
| 2006.202 | A Randomized, Placebo-Controlled, Double-Blind Phase II Study of Sequential Administration of Tarceva_ (Erlotinib) or Placebo in Combination with Gemcitabine/Platinum as First-Line Treatment in Patients with Stage IIIB/IV Non-Small Cell Lung Cancer (NSCLC) | Prof. Mok Tony |
| 2015.632 | A Randomized, Placebo Controlled Phase 3 Study of ABT-414 with Concurrent Chemoradiation and Adjuvant Temozolomide in Subjects with Newly Diagnosed Glioblastoma (GBM) with Epidermal Growth Factor Receptor (EGFR) Amplification (Intellance 1) |
Dr. LOONG Herbert H.F. 龍浩鋒 |
| 2011.183 | A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment with Exenatide Once Weekly in Patients with Type 2 Diabetes Mellitus | Dr. TSANG Chiu Chi |
| 2011.182 | A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment with Exenatide Once Weekly in Patients with Type 2 Diabetes Mellitus | Dr. LUK Andrea On Yan |
| 2011.178 | A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment with Exenatide Once Weekly in Patients with Type 2 Diabetes Mellitus | Prof. YAN Bryan Ping Yen |
| 2011.175 | A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment with Exenatide Once Weekly in Patients with Type 2 Diabetes Mellitus | Prof. WONG Samuel Yeung Shan |
| 2011.152 | A Randomized, Placebo Controlled Clinical Trial to Evaluate Cardiovascular Outcomes After Treatment with Exenatide Once Weekly in Patients with Type 2 Diabetes Mellitus | Dr. OZAKI Risa |
| 2012.225 | A Randomized, Phase III, Multicenter, Double Blind, Placebo-Controlled Study Evaluating the Efficacy and Safety of MetMAb in Combination With Tarceva (Erlotinib) in Patients with Met Diagnostic-Positive Non-Small Cell Lung Cancer (NSCLC) who have Received Standard Chemotherapy for Advanced or Metastatic Disease | Prof. Mok Shu-Kam |
| 2008.286 | A Randomized, Parallel, Controlled Study to Evaluate the Role of Pretreatment Drug Susceptibility Tests in the Selection of Regimens of Chemotherapy for Retreatment of Relapsed Pulmonary TB in Guangzhou | Prof Hui David Shu Cheong |
| 2006.159 | A Randomized, Parallel Group, Placebo-Controlled, Double Blind Study to Assess the Safety and Tolerability of SB-681323 at 7.5mg Daily Dose for 28 days and its Effect on the Levels of Serum C-Reactive Protein (CRP) in Subjects with Rheumatoid Arthritis (RA) | Prof. Li Kwok Ming Edmund |
| 2005.095 | A Randomized, Open-labeled, Parallel, Comparative Study of the Efficacy and Tolerability of Rosuvastatin in LDL-C Reduction Using Different Dosing Regimes of 5mg Daily, 10mg Daily and 10mg Alternate day in Hong Kong Chinese Type 2 Diabetic Patients | Dr. Chow Chun Chung Francis |
| 2021.182 | A Randomized, Open-Label, Two-Arm Study to Evaluate the Safety, Efficacy, and Pharmacodynamic Effects of Pozelimab and Cemdisiran Combination Treatment in Patients with Paroxysmal Nocturnal Hemoglobinuria Who Have Received Pozelimab Monotherapy |
Dr. WONG Raymond Siu Ming 王紹明 |
| 2010.512 | A Randomized, Open-label, Single-dose, Two-period, Crossover Study to Demonstrate the Bioequivalence of the Fixed Dose Combination (FDC) of lamivudine and adefovir dipivoxil (100mg/10mg) to Heptodin_ (100mg) and Hepsera_ (10mg) | Professor Tomlinson Brian |
| 2023.069 | A Randomized, Open-label, Phase 3 Trial of Dato-DXd Plus Pembrolizumab vs Pembrolizumab Alone in Treatment-naïve Subjects with Advanced or Metastatic PD-L1 High (TPS ≥50%) Non-small Cell Lung Cancer Without Actionable Genomic Alterations (TROPION-Lung08) | Dr. LOONG Herbert Ho Fung |
| 2022.392 | A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab With Chemotherapy for the First-Line Treatment of Patients With Metastatic Non–Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations | Dr. LI Molly Siu Ching |
| 2023.102 | A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1 | Prof. YEO Winnie Ming Ming |
| 2023.267 | A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Patients With Hormone Receptor-Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2−) (HER2 IHC0 or HER2-low [IHC 1+, IHC 2+/ISH−]) Inoperable, Locally Advanced, or Metastatic Breast Cancer and Have Received Endocrine Therapy | Prof. YEO Winnie |
| 2024.409 | A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician’s Choice in Participants With Endometrial Cancer Who Have Received Prior Platinum-based Chemotherapy and Anti-PD-1/PD-L1 Immunotherapy | Prof. YEO Winnie |
| 2022.286 | A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice and Pembrolizumab in Patients With Previously Untreated, Locally Advanced, Inoperable, or Metastatic Triple-Negative Breast Cancer, Whose Tumors Express PD-L1 |
Prof. YEO Winnie 楊明明教授 |
| 2009.110 | A Randomized, Open-Label, Parallel-Group, Multicenter Study to Determine the Efficacy and Long-Term Safety of Albiglutide Compared With Insulin in Subjects With Type 2 Diabetes Mellitus | Dr. Ozaki Risa |
| 2009.121 | A Randomized, Open-Label, Parallel-Group, Multicenter Study to Determine the Efficacy and Long-Term Safety of Albiglutide Compared With Insulin in Subjects With Type 2 Diabetes Mellitus | Dr Tsang Chiu Chi |
Page 221 of 262.